24 results
8-K
EX-10.1
SQZB
SQZ Biotechnologies Co
7 Jul 23
Departure of Directors or Certain Officers
4:30pm
signature.
On behalf of the entire leadership team, thank you for your continued hard work and dedication toward SQZ’s success.
Sincerely,
/s/ David First
David First
Acknowledged and agreed (return by July 12, 2023):
EMPLOYEE
PRE 14A
SQZB
SQZ Biotechnologies Co
10 Apr 23
Preliminary proxy
4:31pm
held clinical development leadership roles at Bristol-Myers Squibb Corporation and Millennium Pharmaceuticals. Before joining the biopharmaceutical … . Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division
8-K
SQZB
SQZ Biotechnologies Co
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
of the Plan, the timing and outcome of the Company’s clinical trials, the Company’s cash use and availability, and leadership. These forward-looking
8-K
EX-99.1
SQZB
SQZ Biotechnologies Co
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
and I would like to sincerely thank Armon for his vision and leadership at SQZ over the past decade and his willingness to remain available to advise … strategic prioritization, the timing and outcome of the company’s clinical trials, cash use and availability, leadership and upcoming events and presentations
8-K
EX-99.1
muobpio1
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
fdxrnif1hrtgwhz39ppc
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
EX-99.1
eiae5h
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
EX-99.1
v93fr ikqhpu7awxd
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
DEF 14A
sxgqb
26 Apr 21
Definitive proxy
5:00pm
10-K
d0tuk 4ejbi1t6g
18 Mar 21
Annual report
6:31am
424B4
n020hpxsf
12 Feb 21
Prospectus supplement with pricing info
5:10pm
DRS
r9zx wa9fd
1 Feb 21
Draft registration statement
12:00am
10-Q
ue3xoso0 lyuemquq
10 Dec 20
Quarterly report
4:46pm
424B4
jk9x3kus7pqls
30 Oct 20
Prospectus supplement with pricing info
4:54pm